PlexusDx sources all compounded medications exclusively from licensed 503A compounding pharmacies, which operate under strict FDA oversight and state pharmacy board regulations
Therefore, given the association with improved nutritional status under semaglutide treatment, this GLP-1RA could be explored in other obesity-related conditions, including fatty liver disease, dyslipidemia, hypertension, and potentially even cancer
The guidelines recommend evidence-based, personalized treatment approaches, including pelvic floor physical therapy, oral medications, intravesical therapies, and neuromodulation, thereby encouraging standardized patient care and supporting the wider adoption of advanced IC/BPS treatment options
Here are a few foundational strategies I often discuss with clients: Eat smaller meals more often instead of forcing large portions
While semaglutide is FDA-approved for type 2 diabetes and weight loss, type 1 patients exploring off-label use must understand both the theoretical benefits and real risks involved
This could potentially provide a tool to distinguish individuals with different pathophysiology